Progress to Date

Demonstrating the Efficiency of the Sendai Virus Vector
Pseudotyping a SIV Vector with the SeV H&FN Proteins
Gene Transfer Efficiency from SeV Pseudotyped SIV
What remains to be done to get SIV to the clinic?


Sendai Virus on the cover of Molecular Therapy

Demonstrating the Efficiency of the Sendai Virus Vector^Top

The Consortium has been working with DNAVEC for some years on various aspects of this work. Initially we demonstrated the efficiency the Sendai Virus (SeV) vector in the respiratory epithelium (Griesenbach et al 2002 , Ferrari et al 2004 & Griesenbach et al 2010).

However, while incredibly efficient the duration of expression from SeV was very poor as the vector system is entirely RNA based and persists in the cells for only a few days.

The efficiency of SeV was largely due to the function of its coat proteins.

 

Pseudotyping a SIV Vector with the SeV H&FN Proteins^Top

The early promise of the SeV led DNAVEC to clone the SeV H&FN proteins and create a novel Simian immunodeficiency virus vector with the H&FN proteins in order to re-target it to respiratory epithelia (Kobayashi et al 2003).

 


Long-lived expression.

3 doses of SIV without loss of activity

Gene Transfer Efficiency from SeV Pseudotyped SIV^Top

Over the past few years the consortium has been assessing the gene transfer efficiency of the pseudotyped SIV in a number of models (Mitomo et al 2010).

We have demonstrated that the vector has long lived expression in the murine airways with high levels of reporter gene activity observed for at least two years post administration (right).

More significantly, we have demonstrated that the vector can be re-administered twice to mice without any loss of activity relative to the first dose. This is major advance because no other viral vector has been shown to be repeatable in this manner, not with the associated high levels of expression (left).

 

What remains to be done to get this to the clinic?^Top

Despite thie progress, many years of work will likely be required if this vector is to be used in the clinic for CF. Much optimisation of the vector production process is required to increase the yield of vector produced and to provide an efficient expression cassette.

Most of this current work is highly publication sensitive so sadly it cannot be discussed here yet.

Site map

 

Home
News
Contact Details
Follow us on Facebook
Events & Fundraising
Careers
Site Feedback
Site Search
The CF Trust

 

Information for Patients on Our Clinical Trial
Latest Clinical Trial News
Contact Details
Patient Identification Centres
Frequently Asked Questions

 

Consortium Members' Internal Website
About Us
How the Consortium Works
Profiles of the Strategy Group
Milestones
Community Review
Prof David Porteous OBE
Oxford University Gene Medicine
Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

 

Our Research
Optimisation of pDNA
Aerosol Delivery
Viral Vectors Development
Assay Development
Core Facilities
Consortium Patents

 

Clinical Programme
GL67A/pGM169
Clinical Team
Tracking Study
The Run-in Study
Single Dose Clinical Trial
Multi Dose Clinical Trial

 

Cystic Fibrosis
What is CF?
History of CF
Discovery of the CFTR Gene
What Causes CF?
CFTR Protein Structure
Cystic Fibrosis Links

 

Funding
EME
DPFS
Gene Therapy
Introduction to CF Gene Therapy
Why use Gene Therapy for CF?
Other CF Gene Therapy Groups
Examples of Successful Gene Therapy
Gene Therapy Links

 

Publications
Publications in Journals
Conference Posters & Presentations
JustGeneTherapy Lecture, Sept 2012
Book Chapters
Lectures
Open Access Publications
Latest Publications

 

Medical Futures Innovation Award 2011
Introductory Video
What is a Lentivirus
Production of Lentiviruses
Progress to Date
DNAVec
Photo Gallery